COVID-19 Äڷγª¹ÙÀÌ·¯½º : ´ç´Ü¹éÁúÀÇ ±Û¸®Ä ½Çµå¿Í ±¸Á¶ ¿¹Ãø ¹× Àΰ£ CD26°úÀÇ »óÈ£ÀÛ¿ë
- ÀúÀÚNaveen Vankadari , Jacqueline A. Wilce Àú
- ÃâÆÇ»ç¾ÆÁø
- ÃâÆÇÀÏ2020-07-12
- µî·ÏÀÏ2020-12-21
- SNS°øÀ¯
- ÆÄÀÏÆ÷¸ËPDF
- ÆÄÀÏÅ©±â96MB
- °ø±Þ»çYES24
-
Áö¿ø±â±â
PC
PHONE
TABLET
ÇÁ·Î±×·¥ ¼öµ¿¼³Ä¡
ÀüÀÚÃ¥ ÇÁ·Î±×·¥ ¼öµ¿¼³Ä¡ ¾È³»
¾ÆÀÌÆù, ¾ÆÀÌÆеå, ¾Èµå·ÎÀ̵åÆù, ÅÂºí¸´,
º¸À¯ 1, ´ëÃâ 0,
¿¹¾à 0, ´©Àû´ëÃâ 9, ´©Àû¿¹¾à 0
Ã¥¼Ò°³
The recent outbreak of pneumonia-causing COVID-19 in China is an urgent globalpublic health issue with an increase in mortality and morbidity. Here we report
our modelled homo-trimer structure of COVID-19 spike glycoprotein in both closed
(ligand-free) and open (ligand-bound) conformation, which is involved in host cell
adhesion. We also predict the unique N- and O-linked glycosylation sites of spike
glycoprotein that distinguish it from the SARS and underlines shielding and
camouflage of COVID-19 from the host the defence system. Furthermore, our
study also highlights the key finding that the S1 domain of COVID-19 spike
glycoprotein potentially interacts with the human CD26, a key immunoregulatory
factor for hijacking and virulence. These findings accentuate the unique features of
COVID-19 and assist in the development of new therapeutics.
µî·Ï»óÇ¥
Emerging Microbes
¸ñÂ÷
Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Ư¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: ȯ°æ¿¡ Áö¼ÓÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22
Á¦ 2Æí ¿¬±¸³í¹®
Emerging WuHan (COVID-19) coronavirus: glycan shield and structure
prediction of spike glycoprotein and its interaction with human CD26
1. Abstract 23
2. Introduction 23
3. Acknowledgements 26
4. Disclosure statement 26
5. References 26